External Control Arms in Japan: A Systematic Case Analysis of Documented Regulatory Implementation and Uncertainty Management.

IF 4.9 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Clinical Pharmacology & Therapeutics Pub Date : 2026-10-01 Epub Date: 2026-07-25 DOI:10.1002/cpt.70406
Suguru Okami, Alexandros Sagkriotis
{"title":"External Control Arms in Japan: A Systematic Case Analysis of Documented Regulatory Implementation and Uncertainty Management.","authors":"Suguru Okami, Alexandros Sagkriotis","doi":"10.1002/cpt.70406","DOIUrl":null,"url":null,"abstract":"<p><p>External control arms (ECAs) have emerged as important tools to provide benchmark evidence on comparator effectiveness and thereby support regulatory decision making in situations where randomized controlled trials are difficult to conduct. However, how key methodological elements for ECAs are documented and implemented in practice and how residual uncertainty is managed at the time of approval remain unclear. Regulatory approvals of new medical products in Japan between 2019 and 2024 were systematically screened to identify cases employing ECAs. Among 674 eligible approvals screened from 835 approvals identified, 23 cases using ECAs were included and evaluated using a structured framework of 20 key attributes derived from regulatory guidance and methodological recommendations across planning, selection, design, analysis, and reporting domains. The post-marketing requirements associated with each approval were also analyzed to assess how residual uncertainty was addressed following approval. ECAs were predominantly used in settings characterized by rare diseases and small patient populations. Although attributes related to study planning and data-source selection were relatively well described in public documentation, there was substantial heterogeneity in the documentation of design and analysis elements. In particular, explicit specifications of estimands and approaches to handling intercurrent events and missing data were inconsistently described. Residual uncertainty was frequently addressed through post-marketing requirements, often involving studies of efficacy considerations and long-term surveillance, supporting a lifecycle-based approach to uncertainty management. These findings highlight opportunities to enhance transparency and consistency in the documentation of ECA-based evidence and to further develop structured approaches to uncertainty management in regulatory practice.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":" ","pages":"1068-1080"},"PeriodicalIF":4.9000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401665/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cpt.70406","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

External control arms (ECAs) have emerged as important tools to provide benchmark evidence on comparator effectiveness and thereby support regulatory decision making in situations where randomized controlled trials are difficult to conduct. However, how key methodological elements for ECAs are documented and implemented in practice and how residual uncertainty is managed at the time of approval remain unclear. Regulatory approvals of new medical products in Japan between 2019 and 2024 were systematically screened to identify cases employing ECAs. Among 674 eligible approvals screened from 835 approvals identified, 23 cases using ECAs were included and evaluated using a structured framework of 20 key attributes derived from regulatory guidance and methodological recommendations across planning, selection, design, analysis, and reporting domains. The post-marketing requirements associated with each approval were also analyzed to assess how residual uncertainty was addressed following approval. ECAs were predominantly used in settings characterized by rare diseases and small patient populations. Although attributes related to study planning and data-source selection were relatively well described in public documentation, there was substantial heterogeneity in the documentation of design and analysis elements. In particular, explicit specifications of estimands and approaches to handling intercurrent events and missing data were inconsistently described. Residual uncertainty was frequently addressed through post-marketing requirements, often involving studies of efficacy considerations and long-term surveillance, supporting a lifecycle-based approach to uncertainty management. These findings highlight opportunities to enhance transparency and consistency in the documentation of ECA-based evidence and to further develop structured approaches to uncertainty management in regulatory practice.

日本的外部控制武器:文件化法规实施与不确定性管理的系统案例分析。
外部对照装置(eca)已成为提供比较器有效性基准证据的重要工具,从而在难以进行随机对照试验的情况下支持监管决策。然而,eca的关键方法要素如何在实践中被记录和实施,以及在批准时如何管理剩余不确定性,这些问题仍然不清楚。系统筛选了2019年至2024年间日本新医疗产品的监管批准,以确定采用eca的病例。在从835个批准中筛选的674个合格批准中,包括23个使用eca的案例,并使用20个关键属性的结构化框架进行评估,这些属性来自规划、选择、设计、分析和报告领域的监管指导和方法建议。还分析了与每个批准相关的上市后要求,以评估批准后如何解决剩余不确定性。eca主要用于以罕见疾病和小患者群体为特征的环境。虽然与研究计划和数据源选择相关的属性在公共文献中描述得相对较好,但在设计和分析元素的文献中存在实质性的异质性。特别是,对评估的明确规范和处理交互事件和缺失数据的方法的描述不一致。剩余不确定性经常通过上市后的要求来解决,通常涉及疗效考虑和长期监测的研究,支持基于生命周期的不确定性管理方法。这些发现突出了提高基于eca的证据文件的透明度和一致性以及进一步发展监管实践中不确定性管理的结构化方法的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
12.70
自引率
7.50%
发文量
290
审稿时长
2 months
期刊介绍: Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书